Development of quality metrics for ambulatory care in pediatric patients with tetralogy of Fallot by Villafane, Juan et al.
OR I G I N A L A R T I C L E
Development of quality metrics for ambulatory care in pediatric
patients with tetralogy of Fallot
Juan Villafane MD, FACC1 | Thomas C. Edwards MD, FACC2 |
Karim A. Diab MD, FACC3 | Gary M. Satou MD4 | Elizabeth Saarel MD, FACC5 |
Wyman W. Lai MD, MPH, FACC6 | Gerald A. Serwer MD7 |
Peter P. Karpawich MD, FACC8 | Russell Cross MD, FACC9 |
Russell Schiff MD, FACC10 | Devyani Chowdhury MD, FACC11 |
Thomas J. Hougen MD, FACC12
1Department of Pediatrics (Cardiology),
University of Kentucky, Lexington,
Kentucky, USA
2Department of Pediatric Cardiology,
University of Central Florida, Orlando,
Florida, USA
3Department of Pediatric Cardiology, Rush
University Medical Center, Chicago, Illinois,
USA
4Department of Pediatric Cardiology, David
Geffen School of Medicine at UCLA, Los
Angeles, California, USA
5Department of Pediatric Cardiology,
Cleveland Clinic Foundation, Cleveland,
Ohio, USA
6Division of Pediatric Cardiology, Children’s
Hospital of Orange County, Orange,
California, USA
7Department of Pediatric Cardiology,
University of Michigan Health System, Ann
Arbor, Michigan, USA
8Department of Pediatric Cardiology, Wayne
State University School of Medicine, Detroit,
Michigan, USA
9Department of Pediatric Cardiology, George
Washington University, Washington, DC, USA
10Department of Pediatric Cardiology,
Cohen Children’s Medical Center of New
York, Queens, New York, USA
11Cardiology Care for Children, Lancaster,
Pennsylvania, USA
12Department of Cardiology, Children’s
National Heart Institute, Arlington, Virginia,
USA
Correspondence
Juan Villafane, 743 East Broadway, Suite
300, Louisville, KY 40202.
Email: juanvillaf@yahoo.com
Abstract
Objective: The objective of this study was to develop quality metrics (QMs) relating to the ambu-
latory care of children after complete repair of tetralogy of Fallot (TOF).
Design: A workgroup team (WT) of pediatric cardiologists with expertise in all aspects of ambula-
tory cardiac management was formed at the request of the American College of Cardiology (ACC)
and the Adult Congenital and Pediatric Cardiology Council (ACPC), to review published guidelines
and consensus data relating to the ambulatory care of repaired TOF patients under the age of 18
years. A set of quality metrics (QMs) was proposed by the WT. The metrics went through a two-
step evaluation process. In the first step, the RAND-UCLA modified Delphi methodology was
employed and the metrics were voted on feasibility and validity by an expert panel. In the second
step, QMs were put through an “open comments” process where feedback was provided by the
ACPC members. The final QMs were approved by the ACPC council.
Results: The TOF WT formulated 9 QMs of which only 6 were submitted to the expert panel; 3
QMs passed the modified RAND-UCLA and went through the “open comments” process. Based
on the feedback through the open comment process, only 1 metric was finally approved by the
ACPC council.
Conclusions: The ACPC Council was able to develop QM for ambulatory care of children with
repaired TOF. These patients should have documented genetic testing for 22q11.2 deletion. How-
ever, lack of evidence in the literature made it a challenge to formulate other evidence-based
QMs.
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1 | INTRODUCTION
Tetralogy of Fallot (TOF) is the most common cyanotic heart defect
accounting for 7%–10% of all congenital heart defects (CHD).
Although the surgical mortality is low, there still exists significant
morbidity during mid- and long-term follow-up. Optimal longitudinal
ambulatory care is essential and should focus on preventing any
complications after TOF surgical repair1,2 and quality of life for the
patients.
The imperative to develop ambulatory QMs (QMs) is based on
the recognition that the number of children with CHD successfully
treated is rapidly increasing and they face new challenges as they
age.3 Very few guidelines for the outpatient management of patients
with CHD are available.4–6 The American College of Cardiology
(ACC) has developed several clinical performance measures to evalu-
ate quality of care, to stimulate quality improvement, and to test the
effectiveness of interventions provided.7–9 However, until now,
standardized quality indicators for the outpatient management of
pediatric patients with repaired TOF have not been developed. QMs
can address issues related to optimal medical management. This
paper demonstrates the development of QMs and key issues that
surfaced during the process.
2 | METHODS
2.1 | Scope of project
A subcommittee of the ACC Adult Congenital and Pediatric Cardiol-
ogy Council (ACPC) sought to develop several QMs that would indi-
cate best practice in outpatient care of pediatric patients after
repair of uncomplicated TOF. The task of the working team (WT)
was to create quality metrics that would help to improve patient
outcome and decrease practice variation by standardizing care of
these patients.7
2.2 | Work process
The WT consisted of 11 pediatric cardiologists, including a team leader.
This group met at regular intervals to: (1) discuss the scope of the pro-
ject; (2) define the study population in an ambulatory setting; and (3)
perform a literature search including any relevant practice guidelines
that help formulate candidate quality-of-care indicators. The WT was
then divided into smaller groups of 2–3 WT members to review most
aspects of ambulatory care for pediatric patients with repaired TOF. A
total of 9 QMs were originally proposed by the entire team (Table 1).
Three of the QMs were eliminated by the WT after feedback from
ACC ACPC QM steering committee chairs. The remaining six QMs
were submitted for voting by an expert panel formulated by represen-
tation from 9 national and international CHD organizations. QMs were
analyzed for clinical relevance, ease of measurement, and feasibility for
widespread application. Three metrics passed the RAND10 process;
however, only one of these 6 QMs passed the “open comments” and
received final approval by the ACPC. These and other QMs for pediat-
ric ambulatory care were recently published.11
3 | RESULTS
3.1 | Literature review
No uniform approach exists for the postoperative ambulatory care of
children with TOF in part, due to: (1) absence of longitudinal studies in
this age group and (2) variability of the outpatient management from
institution to institution. Wernovsky et al., provided a framework for
outpatient follow-up of complex CHD based on a review of published
literature, the experience of a single academic center, and a national
quality improvement collaboration.12,13 A group from Cincinnati Child-
ren’s Hospital Medical Center developed a set of recommendations for
follow-up of TOF patients. Their recommendations have been added
to the national guidelines clearing house database.14 The Cincinnati
group developed most of their recommendations by way of consensus
TABLE 1 Quality metrics for outpatients with uncomplicated tetralogy of Fallot
Scope of metrics Quality metric numeratora
Cardiac catheterizationb Cardiac catheterization for significant residual defect, ventricular dysfunction or cyanosis
Surgical reportb Report present in medical record at initial postoperative visit
Exercise testingb  1 exercise test between 10 and 18 years of age
Timing of postoperative outpatient visitsc Repaired TOF patients with at least 1 outpatient cardiology visit in the past 15 months
Electrocardiographic testingc All postoperative TOF patients with a least 1 ECG in the past 15 months
Ambulatory electrocardiographic monitoringc At least 1 Holter performed over the past 5 years
Echocardiographyc Annual echocardiogram in the past 15 months
Magnetic resonance imagingb  1 cardiac MRI between 8 and 18 years of age
Genetic testingc Patients should have documented genetic testing for 22q 11.2 deletion
aDenominator for all metrics: all postoperative tetralogy of Fallot outpatients.
bThree metrics eliminated by work team.
cSix metrics were rated by an expert panel on validity1–9 and feasibility.1–9
Only genetic testing was approved.
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since the body of evidence supporting most of their recommendations
was considered “low quality.” Follow-up indicators included annual
office visits, ECG, and annual echocardiograms at least through 10
years of age. Chest x-rays, cardiac magnetic resonance imaging (MRI),
exercise testing, and ambulatory ECG monitoring were recommended
at longer time intervals. The guidelines from the ACC/American Heart
Association (AHA) 2008 and the European Society of Cardiology (ESC)
2010 for the management of adults with CHD were used by the WT
as a resource in formulating the QMs.5,6 A few published articles on
QMs in pediatric cardiology that were applicable to this project were
reviewed by the WT.7–9,15
3.2 | Proposed quality metrics
Following several WT meetings, 9 candidate QMs were defined based
on feasibility and reliability of data as well as potential impact on the
specific QM in patient outcome.
3.2.1 | Timing of outpatient visits after corrective surgery
This QM was based on the WT consensus as there was no specific
standard on the timing of postoperative outpatient visits for TOF pedi-
atric patients, especially during infancy. The ACC/AHA 2008 and other
guidelines recommended at least annual follow-up for older patients
with TOF.5,6,12–14,16 This QM failed to be approved due to insufficient
scientific data to support specific timing intervals for follow-up visits.
Postoperative TOF patients have different severity of defects, and
types of surgical procedures, for example, infundibular muscle resection
with VSD closure versus a transannular patch. Therefore, some
patients may require being seen less frequently than others.
3.2.2 | Echocardiography
A two-dimensional and Doppler echocardiogram provides a useful non-
invasive method for the detection of residual lesions as well as assess-
ment of right ventricular size, systolic pressure and function and LV
function. Serial measurements may also be helpful in monitoring the
progression of any residual lesions. The timing of such evaluations is
the subject of much debate with no consensus on the frequency of
follow-up testing. Although there is no conclusive evidence to adopt
the use of annual echocardiography as a QM, the WT reached a con-
sensus of a yearly study during follow-up.5,17 Echocardiographic testing
should enable better patient management following repair of TOF and
can be helpful in determining the need for additional testing such as
cardiac catheterization or MRI.
3.2.3 | MRI
The right ventricle (RV) and great arteries become difficult to evaluate
by echocardiography in older patients with increasing body size. MRI
correlates well with clinical status and has been the reference standard
for evaluating the RV, particularly with regard to timing of pulmonary
valve replacement. The indication and timing for pulmonary valve
replacement remains controversial and makes appropriate timing of
imaging difficult to establish.5,18–20
3.2.4 | Cardiac catheterization
Diagnostic catheter-based studies for children following repair of TOF
are rarely necessary. In many instances, the combination of high-
quality echocardiography and cardiac MRI/CT will adequately define
residual lesions of concern. However, some patients will benefit from
cardiac catheterization, especially if transcatheter intervention is likely.
Examples include quantifying residual shunts, assessing difficult-to-
image (via echocardiogram) branch pulmonary artery anatomy, and
determining ventricular function and hemodynamics. Therapeutic inter-
vention such as pulmonary artery angioplasty and stenting may also be
provided. This QM was eliminated by the WT because of low feasibility
rating and lack of current support in the literature.
3.2.5 | Surgical report
A postoperative report and discharge summary should be available at
the first postsurgical clinic visit. If a written report is not available, at
minimum, a documentation of personal communication between the
inpatient care team and the outpatient cardiologist should be available.
The receipt of timely intraoperative reports and postoperative recovery
history by the office-based cardiologist is essential to improve transi-
tion of care from inpatient to outpatient. Particular events prior to dis-
charge may alert the outpatient team to areas of concern that may
need added scrutiny. Examples include residual anatomic defects, ven-
tricular dysfunction, history of postoperative arrhythmias and, at times,
psychological issues. Similarly, it is important for the outpatient team to
provide the hospital cardiovascular surgical team with data on the dis-
charged patients. These reports constitute a method of adding to the
surgical results database required for outcome analysis. This QM was
eliminated from consideration because it did not meet operational
standards and could not be supported by any relevant literature.
3.2.6 | Exercise testing
Patients with repaired TOF are at long-term risk for exercise intoler-
ance, arrhythmias, and sudden death due to residual defects, progres-
sive right and left ventricular dysfunction and myocardial scarring.
Cardiopulmonary exercise testing provides a noninvasive method of
quantifying cardiac and pulmonary limitations and may help with risk
stratification of arrhythmias and sudden cardiac death. Serial measure-
ments are helpful in quantifying functional status and risk progression
over time. Existing guidelines have endorsed the use of exercise testing
for follow-up of children and adults with TOF after repair.5,6 Because
there is no established criteria for the timing and frequency of exercise
testing as a QM in pediatric TOF, the WT eliminated this QM before
submission to the expert panel.
3.2.7 | ECG testing
Patients with repaired TOF remain at risk for sudden death; 1.5 to 4.5
deaths per 1000 patients-years at 4 or more years after repair.21 Stud-
ies have reported that prolongation of the QRS is considered to be a
risk factor for sudden death.22 Rarely, late onset heart block has been
reported. In spite of a therapeutic shift to primary intracardiac repair at
an early age, damage to the cardiac conduction system may contribute
to patient morbidity and mortality. A routine ECG screening remains a
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viable and simple test to evaluate any progressive changes in conduc-
tion such as increasing PR interval and QRS duration, and may act as a
marker for any change in RV volume frequently associated with pulmo-
nary regurgitation.23 However, limited evidence exists regarding the
frequency of ECG testing in this setting.
3.2.8 | Ambulatory ECG monitoring (Holter)
Ambulatory ECG monitoring can detect ECG or rhythm disorders in
asymptomatic patients. Among the patients in whom arrhythmias do
occur and who require therapy, this test helps in therapeutic decision
making. There is no published data to determine frequency of
monitoring.5,12,24
3.2.9 | Genetic testing
Systematic determination of potential long-standing support for discov-
ering the underlying genetic causes of CHD has been advocated by the
ACC, AHA, and the American Academy of Pediatrics.25 Genetic testing
might shed light on other system involvement that may provide prog-
nostic information regarding CHD and other organ systems. It facili-
tates counseling regarding recurrence risks and helps to identify other
family members who would benefit from genetic testing. Patients with
TOF demonstrate associated genetic syndromes or chromosome
abnormalities in approximately 25% of cases. In over 15% of cases, a
22q11.2 deletion is found.26–28 Hence, it is logical to encourage
genetic screening for all of these patients. The ACC and AHA guide-
lines for the management of adults with CHD have called for screening
for 22q11 deletion in patients with TOF.5 Similarly, the Canadian Car-
diovascular Society Consensus Conference guidelines on management
of adults with CHD recommended testing for 22q11 deletion in all
patients with TOF.17 Although there is still some debate whether or
not all TOF patients should be tested for 22q11 deletion, the WT con-
cluded that there should be no exception. At least 6% of TOF patients
without arch anomalies have a 22q11 deletion.29 Clinical assessment
for dysmorphic signs of 22q11 may be subtle and difficult to identify,
especially in infants.30,31 Hence, the current QM results in the early
detection of 22q11 deletion in affected TOF patients. Moreover, there
is literature describing an increase in mortality risk in patients who
have this genetic abnormality.32,33
4 | DISCUSSION
The goals of the WT were to develop QMs that would: (1) improve
clinical outcomes for postoperative TOF pediatric patients; (2) decrease
variation in practice patterns; and (3) avoid underuse of vital tests. The
whole process led to approval of 1 QM, genetic testing, for outpatient
management of pediatric TOF patients after surgical repair. These
patients should have documented genetic testing for 22q11.2 deletion.
The development and implementation of QMs intended to guide
the practitioner to assess specific areas in children with repaired TOF
present unique challenges primarily due to variable anatomy, and
changing surgical and interventional techniques that may influence
long term outcomes.
There were several other challenges that the WT encountered: (1)
lack of standardized quality care34,35 in outpatient management of pedi-
atric patients with TOF; (2) lack of long-term prospective studies; and
(3) current guidelines are based mostly on consensus or low levels of
evidence. The WT was invited by ACC/ACPC to design several QMs for
postoperative TOF patients from the neonate to 18 years of age. Essen-
tial features of the selected QMs candidates included: (1) ease of meas-
uring accurately; (2) clearly identifiable data that is easy to retrieve for
analysis; and (3) available scientific evidence to define quality of care.
A guideline from the American Society of Echocardiography, pub-
lished in 2014, on multimodality imaging of repaired TOF patients rec-
ommended echocardiography for routine surveillance annually until the
age of 10, and then every two years afterwards as a class IC recom-
mendation.36 The same document recommended cardiac MRI testing
every 36 months beginning at the age of 10 years in stable patients
and annually in cases of moderate or progressive RV dilation and/or
RV dysfunction. This specific document was published after submission
of candidate QM on MRI and echocardiography by the WT to the
Expert Panel. The testing intervals proposed by the WT on these two
QM differed slightly from the 2014 guideline. This publication was
available for review during the open comment period and hence was
used as a reference. To respect the input from the community and to
give credence to this process, the echocardiography and MRI metrics
were rejected due to the inability to adopt the newly recommended
testing intervals.
The WT experience along with the thoughtful feedback from the
ACC/ACPC committee emphasized the need for ongoing efforts to
develop QMs for the young patients with surgically repaired CHD.
TOF presented particular challenges to define QMs in part because of
the lack of widely established guidelines that met the study criteria.
Nevertheless, although these data is lacking, it should not deter efforts
to acquire this vital information. Consensus expert opinion is often the
usual method deciding what type and when an evaluation or interven-
tion should be done. However, until QM data are acquired, physicians
will only know what is currently practiced and not what evidence-
based criteria indicate.
In conclusion, the creation of QMs for outpatient care of TOF
pediatric patients after surgical repair would help enhance the care pro-
vided and limit the degree of variation adopted by various practices or
institutions. Hence, the objective is that these QMs will be a useful
guide for quality improvement. It would be important to further test
these QMs and their impact on improving clinical outcomes in this
patient population.
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